Major Depressive Disorder Clinical Trials in Atlanta, Georgia
19 recruitingAtlanta, Georgia
Showing 1–19 of 19 trials
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled40 locationsNCT07300969
Recruiting
Phase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
DepressionDepression - Major Depressive DisorderDepression in Adults+3 more
Cybin IRL Limited330 enrolled67 locationsNCT06793397
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 3
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Major Depressive Disorder
Cybin IRL Limited220 enrolled47 locationsNCT06564818
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled42 locationsNCT07076407
Recruiting
Phase 2
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Mild Neurocognitive DisorderMajor Depressive DisorderHIV
National Institute of Allergy and Infectious Diseases (NIAID)186 enrolled40 locationsNCT06705478
Recruiting
Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Sirtsei Pharmaceuticals, Inc.456 enrolled50 locationsNCT06254612
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240
Recruiting
Phase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Major Depressive Disorder
AbbVie195 enrolled31 locationsNCT07276997
Recruiting
Phase 3
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled74 locationsNCT06058013
Recruiting
Phase 3
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled71 locationsNCT06058039
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Major Depressive Disorder
Autobahn Therapeutics, Inc.230 enrolled50 locationsNCT06633016
Recruiting
Phase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled10 locationsNCT06911112
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled46 locationsNCT06775379
Recruiting
Phase 2
JAK Signaling in Depression
Major Depressive Disorder
Emory University100 enrolled1 locationNCT07003997
Recruiting
Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Intra-Cellular Therapies, Inc.470 enrolled60 locationsNCT05850689
Recruiting
Early Phase 1
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Major Depressive Disorder
Emory University140 enrolled1 locationNCT05327699
Recruiting
Phase 4
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Major Depressive Disorder
Axsome Therapeutics, Inc.350 enrolled40 locationsNCT06223880